To survey 30 patients aged 15-65 years with acute severe asthma. They were randomized into one of three different groups: group(A): reiceived salbutamol solution via a nebulizer impelled with oxygen; group (B): received Salbutamol solution via an air compressor-driven nebulizer; and group (C): received Salbutamol via a Metered-dose inhaler attached to a value aerosol holding chamber (Volumatic). After the 6 hours treatment, PEF (peak exhale flow) and other parameters improved significantly in 27 patients. No patient discontinued the trial or transferred to the intensive unit and no cardiovascular adverse events were reported in the study groups. These data showed that the three delivery methods were appropriate to treat subjects with acute severe asthma, however the metered dose inhaler (with holding chamber) was the best choice in the recent medical condition of Vietnam
Asthma ; Aerosols ; Albuterol ; Therapeutics ;

No abstract available.
Albuterol* ; Humans ; Infant* ; Ultrasonics*

No abstract available.
Albuterol* ; Asthma* ; Gases* ; Inhalation*

Background: Effect of salbutamol nebulization in the treatment of acute bronchiolitis in infants is contraverse. Objectives: This study aims to evaluate effect of salbutamol nebulization in infants with bronchiolitis. Subjects and method: Patients were divided into two groups. Treatment group was given salbutamol nebulization with dose of 0.15mg/kg/time, with 2ml sodium 0.9%, 2 times with 30 minute interval and control group. Indicators including Sa02, heart rate and respiratory rate were measured before and after nebuliser of salbutamol. These indicators were compared at times before nebulizing (T1) and after 15 minute (T2), 30 minute (T3), 60 minute (T4). Clinical trends and mean treatment days were compared between two groups. Results: There were 80 infants under 1 year old with bronchiolitis studied from July 2004 to July 2005. Of whom, there were 53 (66.3%) male and 27 (33.7) female. Mean age was 5.4 \xb1 2.69 months. There were 59 infants with mild and moderate forms and 21 infants with severe one. There were 47 infants treated by salbutamol nebulization and 33 infants in the control group. No significant difference of clinical trends and avarage treatment days were found between two groups. Conclusion: Salbutamol nebulization showed no effect on the treatment of acute bronchiolitis in infants.
Bronchiolitis/ therapy ; Albuterol/ diagnostic use

BACKGROUND AND OBJECTIVE: The knowledge about the effects of the nebulized B2-agonist on serum potassium is limited. We aimed to assess the possible hypokalemia following nebulization of salbutamol. METHOD: Seven patients(mean age 60 +- 7.1years) with acute exacerbated asthma were treated with salbutamol nebulization(5mg nebulization at 1 hour interval, 3 times) without concomitant use of steroid or other bronchodilator such as theophylline. RESULTS: There was a significant increase in FEV1, from 46.41+-25.91% at baseline to 62.86+-22.38% at 3 hours after treatment. Serum potassium concentration was significantly decreased, from 3.93+-0.58mEq/L at baseline to 3.41+-0.62mEq/L and 3.46+-0.53mEq/L at 1 hour and 3 hours after third nebulization, repectively. There was a significant prolongation of the QTc interval in EKG from 454.36+-27.07msec at baseline to 479.41+-35.64msec and 505.09+-58. 69msec at 1 hour and 3 hours after third nebulization, respectively. Serum salbutamol concentration was 4.18+-3.39ng/ml at baseline, and increased to 7.69+-6.94ng/ml and 9.84+10.34ng/ ml at 1 hour and 3 hours after treatment, respectively. Magnitude of the hypokalemia and the degree of prolongation of the electrocardiographic QTc interval were significantly correlated with the level of serum salbutamol concenturation. CONCLUSION: The results suggest that cardiac complication could develop due to hypokalemia during repeated salbutamol nebulization. Caution should be done in monitoring of serum potassium concentration when using nebulized salbutamol repeatedly for the treatment of acute exacerbated bronchial asthma.
Albuterol* ; Asthma ; Electrocardiography ; Hypokalemia ; Potassium* ; Theophylline

In the present study, patients were traumatized with muscle-crushing injuries, or they were non-traumstized. The plasma concentration of potassium and sodium were measured before the induction of anesthesia and at selected intervals after the administration of succinylcholine(SCC) in some patients were inhaled the beta2-agonist, salbutamol (about 800 ug) via an endotracheal tube and in the others were not given it. There was no significant difference in the base lines of potassium and sodium between the traumatized and nontraumatized patients. Salbutamol diminished the rise of potassium(-0.30 to 0.09 mEq/L) but did not affect the plasma sodium level. There was no significant side-effect of this agent, but sinus tachycardia was the only thing noted. These results are consistent with the proposed mechanism that the decrease in serum potassium due to salbutamol is most likely a shift of potassium ions from the extracellular space to the intracellular space. Inhalation of salbutamol may be a useful method for the prevention of SCC induced hyperkalemia without any serious side-effect in patients with preexisting hyperkalemia properties who have gone through traums.
Albuterol* ; Anesthesia ; Extracellular Space ; Humans ; Hyperkalemia* ; Inhalation ; Intracellular Space ; Ions ; Plasma ; Potassium ; Sodium ; Succinylcholine* ; Tachycardia, Sinus

BACKGROUND: The peak flowmeter is very useful in monitoring of out-patients as well as those in emergency departments because of its convenience and simplicity with low cost. There have been many studies aimed at determining the accuracy and reproducibility of the peak flow meter in normal population. However, there is a paucity of reports regarding its accuracy in patients with chronic obstructive pulmonary disease(COPD) or asthma. The accuracy of the peak expiratory flow(PEF) measured with a mini-Wright peak flowmeter was assessed by a comparison with the results of a mass flow sensor. METHODS: The PEF measurements were performed in 108 patients aged 19-82 years presenting with either a chronic obstructive lung disease or asthma before and after inhaling salbutamol. The PEF measurements from the mini-Wright flowmeter were compared with those obtained by the calibrated mass flow sensor. RESULTS: The average of the readings taken by the mini-Wright meter were 37-39 l/min higher than those taken by the mass flow sensor. The average percentage error of the mini-Wright meter were higher, ranging less than 300 l/min. The mean of the differences between the values obtained using both instruments (the bias)±limits of agreement(±2 SD) were 37.1±90 l/min for the PEF(p<0.001). CONCLUSIONS: The mini-Wright peak flowmeter overestimated the flows in patients with COPD or asthma. It was also found that the accuracy of the mini-Wright peak flowmeter decreased in its mid to low range. The limits of agreement are wide and the difference between the two instruments is signigicant. Therefore, the measurements made between the two types of machines in patients with asthma or COPD cannot be used in terchangeably.
Albuterol ; Asthma* ; Emergency Service, Hospital ; Flowmeters* ; Humans ; Inhalation ; Outpatients ; Pulmonary Disease, Chronic Obstructive* ; Reading

OBJECTIVETo prepare the antibodies against salbutamol (SAL) with high sensitivity and to develop an indirect competitive enzyme-linked immunoassay (ic-ELISA) for fast detection of SAL.

METHODSThe New Zealand white rabbits were immunized with SAL in a small dose and long period mode. The method of ic-ELISA was optimized and adopted for the detection of a series of SAL samples, then the standard curve of SAL was established. The precision and the recoveries of the method were determined.

RESULTSThe antibodies with high sensitivity towards SAL were prepared with a IC50 of 12.21 ng/ml. The ic-ELISA method for SAL measurement was established, the recoveries of measurement was between 95%-105% and the CV was <3%.

CONCLUSIONThe antibodies against salbutamol have been prepared and an indirect competitive enzyme-linked immunoassay for fast and specific detection of SAL has been developed.

Albuterol ; analysis ; immunology ; Animals ; Antibodies ; immunology ; Enzyme-Linked Immunosorbent Assay ; methods ; Male ; Rabbits

PURPOSE: This study was preformed to demonstrate the improvement of respiratory symptoms and pulmonary function parameters after albuterol inhalation in asthmatic bronchitis using pneumotachography. METHODS: Fifteen asthmatic bronchitis patients admitted to Ewha Womans University Hospital from September in 1998 to July in 1999 were enrolled in this study. Clinical symptoms and pulmonary function parameters including respiratory rate, heart rate, inspiratory tidal volume(Vi), expiratory tidal volume(Ve), peak tidal expiratory flow(PTEF), tidal expiratory flow at 25% of tidal volume(TEF25), mid-expiratory flow(MEF) and mid-inspiratory flow(MIF), compliance, and pulmonary resistance were evaluated by clinical symptom score and pneumotachography before and after albuterol inhalation treatment. RESULTS: The clinical score was decreased significantly after treatment, but heart rate did not show a significant difference. By flow-volume curve, Ve were 7.39+/-2.11 mL/kg, 9.39+/-3.20 mL/kg, and Vi were 7.44+/-2.08 mL/kg, 9.46+/-3.26 mL/kg, and PTEF were 130.1+/-82.1 mL/kg, 123.1+/-64.8 mL/kg before and after treatment, respectively. All the pulmonary function parameters showed no significant differences before and after treatment. CONCLUSIONS: Clinical symptoms were improved after albuterol inhalation treatment in asthmatic bronchitis, but pulmonary function was not recovered after a short-term treatment.
Albuterol ; Bronchitis* ; Compliance ; Female ; Heart Rate ; Humans ; Inhalation ; Respiratory Function Tests* ; Respiratory Rate

BACKGROUND: An assessment of the presence and the degree of reversibility of airflow obstruction is clinically important in patients with asthma or chronic obstructive pulmonary disease. However, the time responses of spirometric parameters in response to bronchodilator have not been well investigated. METHODS: We studied 15 patients with asthma. Spirometric and mini-Wright peak expiratory flow measurements were performed at 15, 30, 45, and 60 minutes after using single dose(200 micro gram) of inhaled bronchodilator, salbutamol. RESULTS: The mean values of forced expiratory volume in one second(FEV1) and forced vital capicaty(FVC) were significantly increased at 60 minutes after using bronchodilator in comparison to 15 minutes. And peak expiratory flow rate measured by either mass flow sensor or mini-Wright peak flow meter were significantly increased at 45 minutes after using bronchodilator in comparison to 15 minutes. CONCLUSIONS: To appropriate evaluation of the bronchodilator response in patients with reversible airflow limitation, it would be useful measuring either FEV1 or PEF at the later time point 60 or 45 minutes in comparison to 15 minutes after using bronchodilator.
Albuterol* ; Asthma ; Forced Expiratory Volume ; Humans ; Peak Expiratory Flow Rate ; Pulmonary Disease, Chronic Obstructive